Genentech Acquires Rights to Cancer Treatment and Genzyme Begins Phase 2 Trial of Oral Treatment for Gaucher Disease
Genentech Acquires Rights to Cancer Treatment and Genzyme Begins Phase 2 Trial of Oral Treatment for Gaucher Disease
City of Industry, CA --(www.FinancialNewsUSA.com)-- 07/27/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Genentech (NYSE: DNA) has entered into an agreement with a small biotech firm to develop treatments for cancer and acute heart problems. The company struck a deal with privately held Inotek Pharmaceuticals for the rights to its Phase II poly-ADP polymerase (PARP) inhibitor program, which is designed to block an enzyme that is thought to help tumor cells repair themselves following chemotherapy, thereby increasing its effectiveness. Biogen Idec Inc. (Nasdaq: BIIB) reported a big boost in revenue during its fiscal 2006 second quarter, but the biotechnology company generated a sizable net loss because of one-time expenses stemming from corporate acquisitions. Cambridge, Mass.-based Biogen said revenue reached $660 million during the quarter ending June 30, up from $606 million in the fiscal 2005 second quarter.
Genzyme Corporation (Nasdaq: GENZ) recently announced that it has begun to treat patients in a Phase 2 clinical trial of Genz-112638, an oral therapy being developed for the treatment of Gaucher disease. Genzyme will conduct the study in patients with Type 1 Gaucher disease at medical centers in Europe, Israel, South America and the United States. Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.
Biotech News
City of Industry, CA --(www.FinancialNewsUSA.com)-- 07/27/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Genentech (NYSE: DNA) has entered into an agreement with a small biotech firm to develop treatments for cancer and acute heart problems. The company struck a deal with privately held Inotek Pharmaceuticals for the rights to its Phase II poly-ADP polymerase (PARP) inhibitor program, which is designed to block an enzyme that is thought to help tumor cells repair themselves following chemotherapy, thereby increasing its effectiveness. Biogen Idec Inc. (Nasdaq: BIIB) reported a big boost in revenue during its fiscal 2006 second quarter, but the biotechnology company generated a sizable net loss because of one-time expenses stemming from corporate acquisitions. Cambridge, Mass.-based Biogen said revenue reached $660 million during the quarter ending June 30, up from $606 million in the fiscal 2005 second quarter.
Genzyme Corporation (Nasdaq: GENZ) recently announced that it has begun to treat patients in a Phase 2 clinical trial of Genz-112638, an oral therapy being developed for the treatment of Gaucher disease. Genzyme will conduct the study in patients with Type 1 Gaucher disease at medical centers in Europe, Israel, South America and the United States. Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.
Biotech News
posted by Bill Austin - Genentech Acquires Rights to Cancer Treatment and Genzyme Begins Phase 2 Trial of Oral Treatment for Gaucher Disease
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home